🔗 Share this article

Former Prime Minister Rishi Sunak has strengthened his campaign for a focused screening programme for prostate cancer.

During a recently conducted interview, he stated being "certain of the immediate need" of implementing such a programme that would be affordable, feasible and "protect countless lives".

His remarks come as the UK National Screening Committee reviews its ruling from half a decade past not to recommend regular testing.

Journalistic accounts indicate the body may continue with its existing position.

Olympic Champion Contributes Support to Campaign

Champion athlete Chris Hoy, who has late-stage prostate cancer, wants men under 50 to be tested.

He suggests decreasing the eligibility age for obtaining a PSA blood screening.

Currently, it is not routinely offered to asymptomatic males who are under 50.

The PSA examination remains disputed however. Levels can rise for causes apart from cancer, such as inflammation, resulting in false positives.

Opponents argue this can cause unnecessary treatment and adverse effects.

Targeted Screening Proposal

The suggested screening programme would concentrate on individuals in the 45-69 age bracket with a genetic predisposition of prostate gland cancer and African-Caribbean males, who encounter double the risk.

This demographic comprises around over a million males in the United Kingdom.

Research projections propose the system would require £25 million annually - or about eighteen pounds per individual - comparable to colorectal and mammary cancer testing.

The assumption envisions one-fifth of suitable candidates would be contacted each year, with a seventy-two percent participation level.

Diagnostic activity (imaging and tissue samples) would need to rise by almost a quarter, with only a modest expansion in healthcare personnel, based on the report.

Clinical Professionals Reaction

Some clinical specialists are doubtful about the benefit of examination.

They assert there is still a risk that men will be treated for the disease when it is not strictly necessary and will then have to experience side effects such as bladder issues and impotence.

One respected urology specialist remarked that "The challenge is we can often identify abnormalities that doesn't need to be treated and we risk inflicting harm...and my concern at the moment is that risk to reward ratio needs adjustment."

Patient Perspectives

Patient voices are also influencing the debate.

A particular example features a sixty-six year old who, after seeking a PSA test, was diagnosed with the condition at the time of fifty-nine and was advised it had spread to his pelvic area.

He has since undergone chemical therapy, radiotherapy and hormone treatment but cannot be cured.

The individual endorses testing for those who are genetically predisposed.

"That is crucial to me because of my boys – they are in their late thirties and early forties – I want them tested as soon as possible. If I had been tested at 50 I am certain I wouldn't be in the position I am now," he stated.

Future Steps

The Screening Advisory Body will have to evaluate the evidence and viewpoints.

Although the latest analysis indicates the consequences for staffing and availability of a examination system would be manageable, some critics have argued that it would take diagnostic capabilities from individuals being cared for for other conditions.

The continuing discussion underscores the multifaceted balance between early detection and likely overtreatment in prostate cancer management.